Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 4,938 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 4,938 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $39.74, for a total transaction of $196,236.12. Following the transaction, the director directly owned 9,900 shares of the company’s stock, valued at $393,426. This represents a 33.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Up 1.0%

NASDAQ ROIV opened at $39.98 on Friday. The firm’s 50 day moving average is $36.10 and its 200-day moving average is $31.97. The company has a market capitalization of $28.88 billion, a PE ratio of -75.43 and a beta of 1.12. Roivant Sciences Ltd. has a 12-month low of $14.50 and a 12-month high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current year.

Analysts Set New Price Targets

ROIV has been the topic of several recent analyst reports. TD Cowen boosted their price target on Roivant Sciences from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Jefferies Financial Group boosted their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Finally, Guggenheim increased their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.64.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its position in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares during the period. Norges Bank bought a new stake in shares of Roivant Sciences during the 4th quarter worth about $112,750,000. Jefferies Financial Group Inc. bought a new stake in shares of Roivant Sciences during the 4th quarter worth about $76,272,000. Baker BROS. Advisors LP grew its stake in Roivant Sciences by 47.4% in the 4th quarter. Baker BROS. Advisors LP now owns 5,555,017 shares of the company’s stock valued at $120,544,000 after buying an additional 1,787,244 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Roivant Sciences by 179.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after buying an additional 1,724,588 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.